



AMR Industry Alliance contributions to tackling antimicrobial resistance: A spotlight on research and science, access and antimicrobial stewardship

Antimicrobial Resistance (AMR) is a complex challenge, requiring a comprehensive approach to address it. Our identified strategies centre around:



Investing in research and science to develop novel diagnostics, antimicrobials and vaccines



Initiatives to support access to a sufficient supply of quality-assured AMR-relevant products



Antimicrobial stewardship to ensure that existing antimicrobials are used appropriately

THE HIGHLIGHTS

Alliance member contributions to tackling AMR (1 April 2021 and 31 March 2023)

RESEARCH AND SCIENCE



Alliance members made significant investments in AMR-relevant R&D.

Approximately **USD 2 billion**

was invested annually by 34 companies in 2021 and 2022 fiscal years.

However, Alliance members **experienced significant challenges affecting decisions about investing:**



82% of surveyed R&D active companies saw **market viability concerns and a lack of appropriate pull incentives/instruments** as significant challenges.



The investment climate for future industry funded R&D efforts is **uncertain**.

71% of surveyed R&D active companies **would increase investment if market conditions improved**.

68% of surveyed R&D active companies would **maintain levels of investment even if market conditions remained unchanged**.



All surveyed R&D active companies **engaged in collaborative R&D activities**, reflecting Alliance member commitment to working together in the fight against AMR.



ACCESS

67% of Alliance members responding to the survey **actively supported access to AMR-relevant products and/or technologies** and did so in diverse ways. Examples include efforts related to:

- product registration with regulatory authorities
- ease of access
- advocacy for approvals
- inclusion in clinical guidelines
- affordability
- product availability
- ensuring high quality products
- collaborative access mechanisms

ANTIMICROBIAL STEWARDSHIP AND APPROPRIATE USE

72% of surveyed Alliance members **implemented actions to support stewardship and the appropriate use** of AMR relevant products and/or technologies. Examples include:



education and awareness raising



generating evidence and tools to support appropriate use



aligning product promotion to AMR stewardship



collecting and/or sharing surveillance data



LOOKING TO THE FUTURE



There is an urgent need for sustainable incentives to stimulate R&D at scale, to feed innovation pipelines and to help secure viable markets.



Strengthening collaboration with the private, public and not-for-profit sectors could support future Alliance activities to improve access to antimicrobials and enhance antimicrobial stewardship across diverse geographies.



[Click here to read more about this work.](#)